Year Established :
1952
Total Assets(USD) :
More than 99,999,999
Total Number of Staff :
more than 1000
Main Competitive Advantages :
Brand Name,International Approvals/Standards,Delivery Term,Production Capacity,Large Product Line,Contract Manufacturing (CRO,CMO),Buyers' Specifications Accepted,Small Orders Accepted,Reputation,Quality Service
Business Type :
Manufacturer
R&D Capacity :
OEM,ODM,Own Brand
Main Sales Markets :
North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Product Range :
API: ACARBOSE, CYCLOSPORINE, TACROLIMUS,FONDAPARINUX SODIUM, LIRAGLUTIDE,MUPIROCIN, POLYMYXIN B SULFATE, CASPOFUNGIN Acetate,DAPTOMYCIN,FUSIDIC ACID,MYCOPHENOLATE MOFETIL
ADC Payload: DM1,DM4, MMAE, MMAF,VcMMAE, Exatecan mesylate,Deruxtecan,Auristatin F,DM1-SMCC,Val-Cit-PAB-MMAE,Belotecan HCl
GLP-1: Liraglutide, Semaglutide and Peptide intermediates
Protected & modified Nucleotide and Nucleoside, Phosphoramidites
Functional Ingredients: Vitamin K2, PQQ, PS, Lycopene, β-carotin, DHA